Loss of Calpain 3 Proteolytic Activity Leads to Muscular Dystrophy and to Apoptosis-associated IkappaBalpha/nuclear Factor KappaB Pathway Perturbation in Mice

Overview

Journal J Cell Biol

Specialty Cell Biology

Date 2001 Jan 3

PMID 11134085

Citations 58

Authors

I Richard

C Roudaut

S Marchand

S Baghdiguian

M Herasse

D Stockholm

Y Ono

L Suel

N Bourg

H Sorimachi

G Lefranc

M Fardeau

A Sebille

J S Beckmann

Affiliations

Soon will be listed here.

Abstract

Calpain 3 is known as the skeletal muscle-specific member of the calpains, a family of intracellular nonlysosomal cysteine proteases. It was previously shown that defects in the human calpain 3 gene are responsible for limb girdle muscular dystrophy type 2A (LGMD2A), an inherited disease affecting predominantly the proximal limb muscles. To better understand the function of calpain 3 and the pathophysiological mechanisms of LGMD2A and also to develop an adequate model for therapy research, we generated capn3-deficient mice by gene targeting. capn3-deficient mice are fully fertile and viable. Allele transmission in intercross progeny demonstrated a statistically significant departure from Mendel's law. capn3-deficient mice show a mild progressive muscular dystrophy that affects a specific group of muscles. The age of appearance of myopathic features varies with the genetic background, suggesting the involvement of modifier genes. Affected muscles manifest a similar apoptosis-associated perturbation of the IkappaBalpha/nuclear factor kappaB pathway as seen in LGMD2A patients. In addition, Evans blue staining of muscle fibers reveals that the pathological process due to calpain 3 deficiency is associated with membrane alterations.

Citing Articles

Challenges and Considerations of Preclinical Development for iPSC-Based Myogenic Cell Therapy.

Sun C, Serra C, Kalicharan B, Harding J, Rao M Cells. 2024; 13(7.

PMID: 38607035 PMC: 11011706. DOI: 10.3390/cells13070596.

CRISPR/Cas9 Genome Editing in LGMD2A/R1 Patient-Derived Induced Pluripotent Stem and Skeletal Muscle Progenitor Cells.

Mavrommatis L, Zaben A, Kindler U, Kienitz M, Dietz J, Jeong H Stem Cells Int. 2023; 2023:9246825.

PMID: 38020204 PMC: 10653971. DOI: 10.1155/2023/9246825.

Calpain activity is negatively regulated by a KCTD7-Cullin-3 complex via non-degradative ubiquitination.

Sharma J, Mulherkar S, Chen U, Xiong Y, Bajaj L, Cho B Cell Discov. 2023; 9(1):32.

PMID: 36964131 PMC: 10038992. DOI: 10.1038/s41421-023-00533-3.

Loss of in Zebrafish, a Model of Limb-Girdle Muscular Dystrophy, Increases Susceptibility to Muscle Defects Due to Elevated Muscle Activity.

Prykhozhij S, Caceres L, Ban K, Cordeiro-Santanach A, Nagaraju K, Hoffman E Genes (Basel). 2023; 14(2).

PMID: 36833417 PMC: 9957097. DOI: 10.3390/genes14020492.

Proteins implicated in muscular dystrophy and cancer are functional constituents of the centrosome.

Winter L, Kustermann M, Ernhofer B, Hoger H, Bittner R, Schmidt W Life Sci Alliance. 2022; 5(11).

PMID: 35790299 PMC: 9259872. DOI: 10.26508/lsa.202201367.

References

Zabel U, Henkel T, Silva M, Baeuerle P . Nuclear uptake control of NF-kappa B by MAD-3, an I kappa B protein present in the nucleus. EMBO J. 1993; 12(1):201-11. PMC: 413192. DOI: 10.1002/j.1460-2075.1993.tb05646.x. View

Sorimachi H, Imajoh-Ohmi S, Emori Y, Kawasaki H, Ohno S, Minami Y . Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and mu-types. Specific expression of the mRNA in skeletal muscle. J Biol Chem. 1989; 264(33):20106-11. View

Sorimachi H, Saido T, Kawasaki H, Sugita H, Miyasaka M, Arahata K . Muscle-specific calpain, p94, is degraded by autolysis immediately after translation, resulting in disappearance from muscle. J Biol Chem. 1993; 268(14):10593-605. View

Roberds S, Leturcq F, Allamand V, Piccolo F, Jeanpierre M, Anderson R . Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell. 1994; 78(4):625-33. DOI: 10.1016/0092-8674(94)90527-4. View

Richard I, Broux O, Allamand V, Fougerousse F, Chiannilkulchai N, Bourg N . Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell. 1995; 81(1):27-40. DOI: 10.1016/0092-8674(95)90368-2. View

Lim L, Duclos F, Broux O, Bourg N, Sunada Y, Allamand V . Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nat Genet. 1995; 11(3):257-65. DOI: 10.1038/ng1195-257. View

Bonnemann C, Modi R, Noguchi S, Mizuno Y, Yoshida M, Gussoni E . Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat Genet. 1995; 11(3):266-73. DOI: 10.1038/ng1195-266. View

Noguchi S, MCNALLY E, Ben Othmane K, Hagiwara Y, Mizuno Y, Yoshida M . Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science. 1995; 270(5237):819-22. DOI: 10.1126/science.270.5237.819. View

Baldwin Jr A . The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996; 14:649-83. DOI: 10.1146/annurev.immunol.14.1.649. View

10.

Matsuda R, Nishikawa A, Tanaka H . Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. J Biochem. 1995; 118(5):959-64. DOI: 10.1093/jb/118.5.959. View

11.

Nigro V, de Sa Moreira E, Piluso G, Vainzof M, Belsito A, Politano L . Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat Genet. 1996; 14(2):195-8. DOI: 10.1038/ng1096-195. View

12.

Heid C, Stevens J, Livak K, Williams P . Real time quantitative PCR. Genome Res. 1996; 6(10):986-94. DOI: 10.1101/gr.6.10.986. View

13.

Fardeau M, Eymard B, Mignard C, Tome F, Richard I, Beckmann J . Chromosome 15-linked limb-girdle muscular dystrophy: clinical phenotypes in Reunion Island and French metropolitan communities. Neuromuscul Disord. 1996; 6(6):447-53. DOI: 10.1016/s0960-8966(96)00387-2. View

14.

Spencer M, Walsh C, Dorshkind K, Rodriguez E, Tidball J . Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity. J Clin Invest. 1997; 99(11):2745-51. PMC: 508121. DOI: 10.1172/JCI119464. View

15.

Straub V, Rafael J, Chamberlain J, Campbell K . Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol. 1997; 139(2):375-85. PMC: 2139791. DOI: 10.1083/jcb.139.2.375. View

16.

Sorimachi H, Ishiura S, Suzuki K . Structure and physiological function of calpains. Biochem J. 1998; 328 ( Pt 3):721-32. PMC: 1218978. DOI: 10.1042/bj3280721. View

17.

Ma H, Fukiage C, Azuma M, Shearer T . Cloning and expression of mRNA for calpain Lp82 from rat lens: splice variant of p94. Invest Ophthalmol Vis Sci. 1998; 39(2):454-61. View

18.

Ono Y, Shimada H, Sorimachi H, Richard I, Saido T, Beckmann J . Functional defects of a muscle-specific calpain, p94, caused by mutations associated with limb-girdle muscular dystrophy type 2A. J Biol Chem. 1998; 273(27):17073-8. DOI: 10.1074/jbc.273.27.17073. View

19.

Penisson-Besnier I, Richard I, Dubas F, Beckmann J, Fardeau M . Pseudometabolic expression and phenotypic variability of calpain deficiency in two siblings. Muscle Nerve. 1998; 21(8):1078-80. DOI: 10.1002/(sici)1097-4598(199808)21:8<1078::aid-mus15>3.0.co;2-q. View

20.

Baghdiguian S, Martin M, Richard I, Pons F, Astier C, Bourg N . Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat Med. 1999; 5(5):503-11. DOI: 10.1038/8385. View